Details of the Drug Formulations

General Information of Drug (ID: DMYCXKL)

• Drug Name: Capmatinib Drug Info
• Synonyms: 1029712-80-8; INCB28060; INC-280; INC280; UNII-TY34L4F9OZ; 2-fluoro-N-methyl-4-(7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl)benzamide; INC28060; INCB-28060; INCB28060(Capmatinib); NVP-INC280; TY34L4F9OZ; Capmatinib (INCB28060); INCB 28060; 2-Fluoro-N-methyl-4-[7-[(quinolin-6-yl)methyl]imidazo[1,2-b]-[1,2,4]triazin-2-yl]benzamide; BenzaMide, 2-fluoro-N-Methyl-4-[7-(6-quinolinylMethyl)iMidazo[1,2-b][1,2,4]triazin-2-yl]-; C23H17FN6O

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Approved	[1]
Hepatocellular carcinoma	2C12.02	Phase 2	[2]
Recurrent glioblastoma	2A00.00	Phase 1	[3]

• Cross-matching ID:
  PubChem CID: 25145656
  CAS Number: 1029712-80-8
  TTD ID: D07OJZ
  ACDINA ID: D00910

Full List of Drug Formulations Containing This Drug

Capmatinib eq 150mg base tablet

Company	Formulation ID	FDA Description
Novartis Pharm	F23099	Colloidal Silicon Dioxide; Crospovidone; Magnesium Stearate; Mannitol; Microcrystalline Cellulose; Povidone; Sodium Lauryl Sulfate; Ferric Oxide; Red Ferric Oxide; Yellow Ferrosoferric Oxide; Hypromellose; Polyethylene Glycol (Peg) 4000; Talc; Titanium Dioxide

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031741)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)